

Special Issue

After Cancer Remission: Tracking Minimal Residual Disease and Relapse

Message from the Guest Editors

This Special Issue of *Cancers*, titled “After Cancer Remission: Tracking Minimal Residual Disease and Relapse”, aims to highlight the latest research and technological innovations in this evolving field. We welcome original research articles, biomarker studies, methodological and computational tools, and comprehensive reviews focusing on MRD detection, molecular monitoring, and relapse prediction across hematologic and solid tumors.

Topics of interest include liquid biopsy and circulating tumor DNA (ctDNA) approaches, multi-omics profiling, single-cell analyses, imaging-based surveillance, and translational strategies linking MRD dynamics to clinical decision-making. By bringing together multidisciplinary perspectives, this Special Issue seeks to advance our understanding of post-remission disease biology and foster the development of personalized monitoring strategies to prevent and preempt cancer relapse.

Guest Editors

Dr. Andriani Charpidou

Dr. Ioannis P. Trontzas

Dr. Emmanouil Panagiotou

Deadline for manuscript submissions

30 November 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/260122

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)